Connor, Clark & Lunn Investment Management (CC&L)
EPZM

Connor, Clark & Lunn Investment Management (CC&L)’s Epizyme, Inc EPZM Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-64,493
Closed -$161K – 1284
2021
Q4 		$161K Buy
+64,493
New +$253K ﹤0.01% 1001
2015
Q2 		– Sell
-18,700
Closed -$351K – 679
2015
Q1 		$351K Sell
18,700
-14,700
-44% -$304K ﹤0.01% 438
2014
Q4 		$630K Buy
+33,400
New +$780K 0.01% 358

Other funds holding EPZM

RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s EPZM Position: Q1 2022 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Epizyme, Inc (EPZM) in Q1 2022, closing a stake of 64,493 shares — an estimated $161K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in EPZM in Q4 2014 and held it in 3 quarters. The position peaked at $630K in Q4 2014. 120 funds tracked by Wall St. Rank hold EPZM as of Q1 2022.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Epizyme, Inc position as of Q1 2022 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 64,493 Epizyme, Inc shares in Q1 2022, an estimated $161K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Epizyme, Inc in Q4 2014 and held it in 3 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Epizyme, Inc position peaked at $630K in Q4 2014.
  • 120 funds tracked by Wall St. Rank held Epizyme, Inc as of Q1 2022.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2022, filed 12 May 2022.